Early observations and pilot data that first suggested a new direction
The concept of synthetic lethality -- where loss of two genes is lethal while loss of either alone is viable -- was first proposed as a therapeutic strategy for BRCA-mutant cancers by two independent groups (Bryant/Helleday and Farmer/Ashworth) in landmark 2005 Nature publications. BRCA1/2-mutant cancers, already deficient in homologous recombination DNA repair, become critically dependent on PARP-mediated base excision repair. Inhibiting PARP in these cells creates an irreconcilable DNA repair catastrophe leading to cell death, while normal cells with intact BRCA compensate and survive. This elegant biological rationale provided a targeted approach that exploited tumor-specific vulnerabilities rather than general cytotoxicity.
Landmark RCTs and pivotal trials that established the evidence base
Olaparib was the first PARP inhibitor to demonstrate clinical efficacy. Study 19, a phase 2 maintenance trial in platinum-sensitive recurrent ovarian cancer, showed that olaparib maintenance doubled progression-free survival versus placebo (8.4 vs 4.8 months), with the greatest benefit in BRCA-mutant patients (11.2 vs 4.3 months). The definitive SOLO-1 trial, a phase 3 RCT published in the NEJM in 2018, demonstrated that first-line olaparib maintenance in BRCA-mutant advanced ovarian cancer reduced the risk of progression or death by 70% (HR 0.30), with median PFS not reached versus 13.8 months for placebo. This unprecedented result established PARP inhibitors as a new standard of care in ovarian cancer.
Follow-up studies, subgroup analyses, and real-world validation
PARP inhibitors expanded beyond BRCA-mutant ovarian cancer across multiple dimensions. The NOVA trial established niraparib as maintenance therapy regardless of BRCA status, with benefit also seen in non-BRCA HRD-positive tumors, broadening the eligible population. The PROfound trial demonstrated olaparib activity in metastatic castration-resistant prostate cancer with HRR gene alterations (BRCA1/2, ATM, and others), leading to prostate cancer approval. Talazoparib was approved for BRCA-mutant metastatic breast cancer after the EMBRACA trial. The concept of homologous recombination deficiency (HRD) as a biomarker beyond BRCA mutations enabled identification of additional responders through genomic scar assays (Myriad myChoice, Foundation Medicine FoundationOne CDx).
Integration into clinical practice guidelines and recommendations
NCCN, ESMO, and SGO guidelines now incorporate PARP inhibitors as standard of care across multiple tumor types. In ovarian cancer, olaparib or niraparib maintenance is recommended after first-line platinum-based chemotherapy for BRCA-mutant and HRD-positive advanced disease. In prostate cancer, olaparib is recommended for mCRPC with HRR gene alterations after progression on androgen receptor-targeted therapy. BRCA testing is now recommended for all ovarian, prostate (metastatic), and pancreatic cancers to identify candidates for PARP inhibitor therapy, fundamentally embedding molecular testing in routine oncology care.
NCCN Guidelines: Ovarian Cancer
PARP inhibitor maintenance (olaparib or niraparib) recommended for BRCA-mutant and HRD-positive advanced ovarian cancer after first-line platinum-based chemotherapy. Olaparib + bevacizumab for HRD-positive regardless of BRCA status.
ESMO Clinical Practice Guidelines: Ovarian Cancer
First-line olaparib maintenance for BRCA-mutant advanced ovarian cancer (Category I evidence). HRD testing recommended for all advanced ovarian cancer to identify niraparib and olaparib+bevacizumab candidates.
Now
Current standard of care and ongoing research directions
PARP inhibitors are established across ovarian, breast, prostate, and pancreatic cancers with ongoing expansion to other HRD-positive tumor types. Key current challenges include PARP inhibitor resistance mechanisms (reversion mutations restoring BRCA, drug efflux pumps, loss of PARP1), management of myelodysplastic syndrome/acute myeloid leukemia risk (rare but serious long-term toxicity), and optimal combination strategies. PARP inhibitor plus immune checkpoint inhibitor combinations are being explored, with the rationale that PARP-induced DNA damage generates neoantigen load to enhance immunogenicity. Ongoing trials investigate earlier-line use, neoadjuvant settings, and expansion to non-HRD tumors through combination-induced HRD-mimicking states.
What is synthetic lethality and how do PARP inhibitors exploit it?+
Synthetic lethality occurs when loss of two genes is lethal while loss of either alone is survivable. BRCA-mutant cancer cells cannot perform homologous recombination repair. When PARP (needed for alternative repair) is also inhibited, the cell accumulates lethal DNA damage. Normal cells with intact BRCA can still repair DNA through homologous recombination, creating tumor-selective killing.
What is HRD and why does it matter beyond BRCA mutations?+
Homologous recombination deficiency (HRD) refers to impaired DNA repair capacity that can result from BRCA1/2 mutations but also from alterations in other HRR genes (ATM, PALB2, RAD51, CHEK2, and others) or epigenetic BRCA silencing. HRD genomic scar assays detect the accumulated DNA damage signature, identifying non-BRCA patients who may also benefit from PARP inhibitors.
Are there long-term safety concerns with PARP inhibitors?+
The most concerning long-term toxicity is therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), occurring in approximately 1-2% of patients on long-term PARP inhibitor therapy. This risk must be weighed against the substantial progression-free survival benefit. Routine blood count monitoring is recommended, and any unexplained cytopenias warrant bone marrow evaluation.
